pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Phase 3 Readout · news · pharmadog
← back to Phase 3 Readout
News · Phase 3 Readout
16
stories
2h
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
7d
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
biospace
8d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
12d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
20d
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy
endpoints
27d
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
28d
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
28d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
29d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
29d
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
fiercebiotech
Jul 27, 26
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
Jul 27, 26
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
Jul 17, 26
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
biospace
Jul 8, 26
Satellos gives early look at Duchenne pill in adults ahead of key data in children
endpoints
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
